At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
In Brief
A Phase 2 clinical trial evaluating Tamibarotene, Azacitidine, and 1 other intervention for Acute Myeloid Leukemia and Myelodysplastic Syndrome. Completed, enrolled 155 participants across 26 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine the activity of tamibarotene in participants with relapsed/refractory (R/R) AML (administered as a monotherapy or in combination with azacitidine), R/R higher-risk MDS (HR-MDS) (administered as a monotherapy or in combination with daratumumab), newly diagnosed treatment naïve AML participants who are unlikely to tolerate standard intensive chemotherapy (administered as a monotherapy or in combination with azacitidine), or lower-risk MDS (LR-MDS) (administered as a monotherapy).
Study Details
Timeline
Interventions
Administered as oral tablets
Administered via intravenous (IV) or subcutaneous (SC) infusion
Administered via IV infusion